<?xml version="1.0" encoding="UTF-8"?>
<p id="para420">The most common serious adverse events were infections in both the lenalidomide group and the observation group. 460 deaths occurred during maintenance treatment, 234 (21%) in the lenalidomide group and 226 (27%) in the observation group, and no deaths in the lenalidomide group were reported as treatment-related (
 <xref rid="sec1" ref-type="sec">appendix p 25</xref>).
</p>
